BioAffinity Technologies Receives Additional $7.7M From Exercise Of Warrants
BioAffinity Technologies Receives Additional $7.7M From Exercise Of Warrants
BioAffinity Technologies 通过行使认股权证额外
$bioAffinity Technologies (BIAF.US)$ today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.
$bioAffinity Technologies (BIAF.US)$今天宣布，通过行使公司2022年9月6日公开发行证券中发行的可交易和不可交易认股权证，将获得约770万美元的额外总收益。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。